The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.
 
Mariana Scaranti
No Relationships to Disclose
 
Raghav Sundar
Honoraria - Bristol-Myers Squibb; Lilly; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai
Travel, Accommodations, Expenses - AstraZeneca; Roche; Taiho Pharmaceutical
 
Robert Daly
No Relationships to Disclose
 
Dearbhaile Catherine Collins
Honoraria - AstraZeneca; Genmab; Pfizer; Roche
Consulting or Advisory Role - Seagen
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genmab; Roche/Genentech
 
David Dolling
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst); Janssen Diagnostics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Spyridon Gennatas
No Relationships to Disclose
 
Bindumalini Rao Baikady
No Relationships to Disclose
 
Stan B Kaye
No Relationships to Disclose
 
Udai Banerji
Employment - Institute of Cancer Research
Honoraria - Astellas Pharma; Lilly
Consulting or Advisory Role - Novartis; Phoenix Solutions
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Sierra Oncology
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Anna Rachel Minchom
Honoraria - Faron Pharmaceuticals
Consulting or Advisory Role - Janssen Oncology
Travel, Accommodations, Expenses - Imugene; Loxo